126.03
price down icon0.69%   -0.8853
 
loading
Schlusskurs vom Vortag:
$126.92
Offen:
$127.2
24-Stunden-Volumen:
447.55K
Relative Volume:
0.27
Marktkapitalisierung:
$19.85B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.44
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
-0.79%
1M Leistung:
-1.83%
6M Leistung:
-16.70%
1J Leistung:
-44.89%
1-Tages-Spanne:
Value
$125.60
$128.25
1-Wochen-Bereich:
Value
$123.21
$129.27
52-Wochen-Spanne:
Value
$110.03
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
Firmenname
Biogen Inc
Name
Telefon
(781) 464-2000
Name
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
7,605
Name
Twitter
@biogen
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
BIIB's Discussions on Twitter

Vergleichen Sie BIIB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BIIB
Biogen Inc
126.06 19.85B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
777.28 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.22 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.34 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.41 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
119.94 234.21B 53.22B 12.86B 14.85B 6.39

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Herabstufung HSBC Securities Buy → Hold
2025-04-04 Herabstufung Argus Buy → Hold
2025-02-11 Eingeleitet Bernstein Mkt Perform
2025-01-02 Herabstufung Piper Sandler Overweight → Neutral
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-16 Herabstufung Stifel Buy → Hold
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-11-18 Herabstufung Needham Buy → Hold
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-14 Eingeleitet Citigroup Neutral
2024-10-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-02-14 Bestätigt Needham Buy
2024-02-14 Herabstufung Wells Fargo Overweight → Equal Weight
2024-01-24 Herabstufung UBS Buy → Neutral
2023-12-20 Fortgesetzt Cantor Fitzgerald Overweight
2023-12-07 Hochstufung Raymond James Mkt Perform → Outperform
2023-09-06 Eingeleitet HSBC Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-24 Bestätigt UBS Buy
2023-05-01 Hochstufung Guggenheim Neutral → Buy
2023-04-17 Hochstufung Piper Sandler Neutral → Overweight
2022-10-26 Hochstufung Goldman Neutral → Buy
2022-10-13 Hochstufung Stifel Hold → Buy
2022-10-07 Hochstufung Argus Hold → Buy
2022-09-28 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-09-28 Hochstufung Mizuho Neutral → Buy
2022-09-28 Hochstufung Robert W. Baird Neutral → Outperform
2022-04-18 Hochstufung Wells Fargo Equal Weight → Overweight
2022-03-08 Herabstufung Stifel Buy → Hold
2022-03-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-04 Bestätigt Barclays Equal Weight
2022-02-04 Bestätigt BofA Securities Neutral
2022-02-04 Bestätigt Cowen Outperform
2022-02-04 Bestätigt Morgan Stanley Overweight
2022-02-04 Bestätigt Needham Buy
2022-02-04 Bestätigt Oppenheimer Outperform
2022-02-04 Bestätigt RBC Capital Mkts Sector Perform
2022-02-04 Bestätigt Robert W. Baird Neutral
2022-02-04 Bestätigt Wedbush Neutral
2022-02-04 Bestätigt Wells Fargo Equal Weight
2022-02-04 Bestätigt Wolfe Research Peer Perform
2022-01-13 Herabstufung Guggenheim Buy → Neutral
2022-01-12 Herabstufung Piper Sandler Overweight → Neutral
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-09-23 Eingeleitet Needham Buy
2021-06-18 Hochstufung Piper Sandler Neutral → Overweight
2021-06-14 Bestätigt Truist Buy
2021-06-11 Hochstufung Bernstein Mkt Perform → Outperform
2021-06-10 Hochstufung UBS Neutral → Buy
2021-06-08 Hochstufung Atlantic Equities Underweight → Neutral
2021-06-08 Bestätigt Barclays Equal Weight
2021-06-08 Hochstufung Citigroup Sell → Neutral
2021-06-08 Bestätigt H.C. Wainwright Buy
2021-06-08 Bestätigt Jefferies Buy
2021-06-08 Bestätigt Morgan Stanley Overweight
2021-06-08 Bestätigt RBC Capital Mkts Sector Perform
2021-06-08 Hochstufung Robert W. Baird Underperform → Neutral
2021-06-08 Bestätigt Stifel Buy
2021-06-08 Hochstufung William Blair Mkt Perform → Outperform
2021-06-07 Hochstufung BofA Securities Underperform → Neutral
2021-06-07 Hochstufung Cowen Market Perform → Outperform
2021-06-07 Hochstufung Raymond James Underperform → Mkt Perform
2021-02-05 Herabstufung DZ Bank Buy → Hold
2021-01-29 Hochstufung Stifel Hold → Buy
2020-11-10 Hochstufung DZ Bank Hold → Buy
2020-11-09 Herabstufung Atlantic Equities Neutral → Underweight
2020-11-09 Herabstufung BofA Securities Neutral → Underperform
2020-11-09 Herabstufung Cowen Outperform → Market Perform
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-11-04 Hochstufung BofA Securities Underperform → Neutral
2020-11-04 Hochstufung Jefferies Hold → Buy
2020-11-04 Hochstufung Wells Fargo Equal Weight → Overweight
2020-10-28 Eingeleitet UBS Neutral
2020-07-27 Hochstufung Morgan Stanley Underweight → Overweight
2020-06-22 Herabstufung Barclays Overweight → Equal Weight
2020-06-22 Bestätigt RBC Capital Mkts Sector Perform
2020-06-09 Herabstufung Bernstein Outperform → Mkt Perform
2020-04-23 Herabstufung Citigroup Neutral → Sell
2020-04-23 Herabstufung Raymond James Mkt Perform → Underperform
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-01-27 Hochstufung Canaccord Genuity Hold → Buy
2019-12-13 Hochstufung Credit Suisse Underperform → Neutral
2019-12-02 Herabstufung Robert W. Baird Neutral → Underperform
Alle ansehen

Biogen Inc Aktie (BIIB) Neueste Nachrichten

pulisher
Jun 18, 2025

Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Dips on Its Part in BRAVE Study - Baystreet.ca

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen

Jun 18, 2025
pulisher
Jun 18, 2025

How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen patents new HTT splicing modulators - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media

Jun 17, 2025
pulisher
Jun 16, 2025

NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 15, 2025

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Biogen Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen: positive Phase 3 data in lupus - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus

Jun 12, 2025

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$48.28
price down icon 0.13%
$107.07
price up icon 2.01%
drug_manufacturers_general PFE
$24.16
price down icon 0.36%
$278.56
price down icon 0.88%
drug_manufacturers_general MRK
$79.05
price down icon 0.70%
drug_manufacturers_general NVS
$120.06
price down icon 0.13%
Kapitalisierung:     |  Volumen (24h):